XML 65 R51.htm IDEA: XBRL DOCUMENT v3.4.0.3
FAIR VALUE MEASUREMENTS - Schedule of Reconciliation of Changes in Fair Value of Level 3 Financial Liabilities (Details) - USD ($)
$ in Thousands
12 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Mar. 31, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]      
(Increase) / decrease in fair value and accretion expense (included within research and development expense)   $ (9)  
Contingently returnable consideration $ 16,131    
Payments received (9,306) 0 $ 0
Fair value, measurements, recurring | Contingent Purchase Consideration      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]      
Beginning balance (4,484) (4,291)  
(Increase) / decrease in fair value and accretion expense (included within research and development expense) (152) (193)  
Contingently returnable consideration 0    
Increase in fair value (21)    
Gross presentation of contingently returnable consideration to contingent purchase consideration (2,636)    
Payments received 0    
Ending balance (7,293) (4,484) (4,291)
Fair value, measurements, recurring | Contingently Returnable Consideration      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]      
Beginning balance 0    
(Increase) / decrease in fair value and accretion expense (included within research and development expense) 0    
Contingently returnable consideration 19,125    
Increase in fair value 3,676    
Gross presentation of contingently returnable consideration to contingent purchase consideration 2,636    
Payments received (9,306)    
Ending balance 16,131 0  
Fair value, measurements, recurring | Contingent Contractual Non-compliance Liability      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]      
Beginning balance $ 0 (49)  
(Increase) / decrease in fair value and accretion expense (included within research and development expense)   49  
Ending balance   $ 0 $ (49)